- An increase in deaths from COVID-19 underscores the persistent danger of the virus and the urgent need for effective protective measures and treatments.
- Soligenix is addressing this need through the development of CiVax, its proprietary, heat-stable COVID-19 subunit vaccine candidate.
- Recent preclinical studies have demonstrated that CiVax can induce rapid and broad protection against multiple COVID-19 variants.
Despite the passage of time since the pandemic, COVID-19 continues to pose a significant global health threat. Recent data from the World Health Organization (“WHO”) indicates that during the 28-day period from Jan. 6 to Feb. 2, 2025, more than 147,000 new COVID-19 cases were reported globally, representing a 16% decrease compared to the previous period (https://ibn.fm/viChU). However, during the same timeframe, approximately 4,500 new deaths were reported, marking a 28% increase. This underscores the persistent danger of the virus and the urgent need for effective protective measures and treatments.
In the United States, the Centers for Disease Control and Prevention (“CDC”) reported that as of April 11, 2025, the levels of acute respiratory illnesses, including COVID-19, remain low (https://ibn.fm/tTcxB). Nevertheless, the virus continues to circulate, and the potential for new…
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN